Primary Cells Market is Expected to Reach USD 2.88 billion by 2030
As per the report published by Kings Research, the global Primary Cells Market was valued at USD 1.23 billion in 2022 and is projected to reach USD 2.88 billion by 2030, growing at a CAGR of 11.41% from 2023 to 2030.
Recent trends in the use of primary cells include increased interest in the development of models for specific disease types and the incorporation of advanced techniques into primary cell research. The use of primary cells in conjunction with 3D cell culture systems serves as a model for advancing research and drug development, aiding in the fight against cancer and other life-threatening diseases. Pharmaceutical and biotechnology companies are increasingly using the product to invent drugs to treat genetic and autoimmune diseases, injuries, and inflammation. Primary cells are also used by pharmaceutical companies for the cytotoxicity of new drugs and drug carriers. As genomics and proteomics develop, interest in the use of primary cells is driving the development of individualized therapies for cancer and other diseases. In addition, stem cell therapies have shown great potential and applications in neurodegenerative diseases, eye diseases, diabetes, dentistry, and more. Thus, the use of such therapies is expected to continue to accelerate market growth.
- Based on origin, the hematopoietic cells segment is growing at a CAGR of 13.12% over the forecast period
- Based on type, the human primary cells segment is expected to dominate with a CAGR of 11.86% through the anticipated timeframe
- Based on application, the pharmaceutical & biotechnology segment is expected to dominate the market over the projected period
- On the basis of region, North America accounted for the largest market value of USD 0.49 billion in 2022
STEMCELL Technologies Inc Collaborated with PBS Biotech Inc to Develop the PBS-MINI Bioreactor
June 2022:STEMCELL Technologies Inc collaborated with PBS Biotech Inc to develop the PBS-MINI bioreactor, which is presently accessible to researchers seeking to expand human stem cell cultures.
Development of Potential Cancer Medicines and Treatments to Boost Market Growth
The research and development of potential cancer therapies and cures is a continuing undertaking over the years. These treatments include checkpoint inhibitors, cancer vaccines, and adoptive cell therapies. Chemotherapy and radiation therapy are still widely used in cancer treatment, but they have been improved to be more specific and less damaging to healthy cells. The use of medicinal plants and natural products in cancer treatment is also continuously developing. Certain plant compounds have shown promising anticancer activity in preclinical studies, and researchers continue to explore their potential uses in cancer treatment. Moreover, researchers and companies are constantly exploring new approaches and improving existing treatments to improve their effectiveness, reduce side effects, and increase survival rates for cancer patients, which further drives market growth.
Advancement in Biomedical Research with 3D Cultures
As research communities have recently transformed substantially to utilize better reagents to improve research, primary cells have been incorporated with new technologies such as 3D cell culture which accelerates the market growth. 3D cell culture techniques are advancing research in several prominent biological areas, including cancer biology and drug development. Furthermore, combining primary cells with 3D cell culture techniques can pave the way for future research and drug development, potentially aiding in the fight against cancer and other life-threatening conditions. The significance of primary cell cultures in early-stage drug development with 3D culture is increasing as techniques for the production and maintenance of high-quality primary cell cultures continue to improve.
North America is Expected to Dominate Over the Forecast Period with a CAGR of 11.37%
The primary cells market is expected to dominate owing to the increasing number of applications in drug discovery and development, personalized medicine, and the study of disease pathology across the region. Primary cells are employed in drug research to investigate the efficacy and toxicity of potential novel medicines. The region's expanding usage of primary cells aims to develop personalised medicines for cancer and other disorders. Researchers from all around the region are working to discover the molecular mechanisms that contribute to diseases including cancer and Alzheimer's. In North America, various companies and research organisations, including Thermo Fisher Scientific, Lonza, Stemcell Technologies, and the American Type Culture Collection (ATCC), specialise in the manufacture and utilisation of primary cells, which promotes the market growth.
Asia Pacific is Projected is Growing at a Fastest Rate With a Forecasted CAGR of 13.16%
The primary cells market in Asia Pacific region is growing rapidly which is supported by the expanding number of applications in drug discovery and development, personalized medicine, and disease pathology research. In drug development, primary cells are used to test the efficacy and toxicity of potential new drugs. The pharmaceutical and biotechnology industries across the region are striving to discover new drugs to improve patient health and improve market position which augments the market growth.
Key Players in the Market are Concentrating on Collaborative Agreements to Expand their Market Share
Significant players in the global primary cells market, include AnaBios Corporation, BioIVT, Cell Biologics, Inc., Corning Incorporated, InvivoGen, Lonza Group Ltd., Merck KGaA, PBS Biotech Inc, PromoCell GmbH, StemBioSys, STEMCELL Technologies, Thermo Fisher Scientific, Inc., ZenBio, Inc., and others. Companies are concentrated on expanding their business through collaboration, acquisition, investment, funding, and partnership strategies.